Acrivon Therapeutics, Inc. Common Stock (ACRV) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 9 Buy, 1 Hold.
The consensus price target is $21.83 (low: $17.00, high: $30.00), representing an upside of 1231.1% from the current price $1.64.
Analysts estimate Earnings Per Share (EPS) of $-2.51 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.24 vs est $-2.51 (beat +90.5%). 2025: actual $-2.02 vs est $-2.03 (beat +0.3%). Analyst accuracy: 0%.
ACRV Stock — 12-Month Price Forecast
$21.83
▲ +1,231.10% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Acrivon Therapeutics, Inc. Common Stock, the average price target is $21.83, with a high forecast of $30.00, and a low forecast of $17.00.
The average price target represents a +1,231.10% change from the last price of $1.64.
Highest Price Target
$30.00
Average Price Target
$21.83
Lowest Price Target
$17.00
ACRV Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Acrivon Therapeutics, Inc. Common Stock in the past 3 months
EPS Estimates — ACRV
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.24
vs Est –$2.51
▲ 947.7% off
2025
Actual –$2.02
vs Est –$2.03
▲ 0.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — ACRV
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
